Anja Gesierich Selected Research

Acute Kidney Injury (Acute Renal Failure)

12/2019

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anja Gesierich Research Topics

Disease

30	Melanoma (Melanoma, Malignant) 05/2024 - 01/2016
14	Neoplasms (Cancer) 05/2024 - 10/2013
8	Uveal melanoma 05/2024 - 10/2013
8	Skin Neoplasms (Skin Cancer) 11/2022 - 01/2016
6	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2017
3	Merkel Cell Carcinoma 11/2022 - 11/2017
2	Encephalitis (Encephalitis, Rasmussen) 12/2022 - 11/2022
2	Glioma (Gliomas) 12/2022 - 11/2022
2	Exanthema (Rash) 01/2021 - 02/2019
2	Sarcoidosis (Schaumann Disease) 10/2020 - 01/2018
2	Brain Neoplasms (Brain Tumor) 01/2020 - 01/2018
2	Basal Cell Carcinoma (Rodent Ulcer) 01/2019 - 01/2017
2	Disease Progression 01/2018 - 01/2017
1	Leukocytosis (Pleocytosis) 11/2022
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Infections 01/2021
1	Neutropenia 01/2021
1	Vitiligo 02/2020
1	Acute Kidney Injury (Acute Renal Failure) 12/2019
1	Lipoid Nephrosis (Glomerulonephritis, Minimal Change) 12/2019
1	Nephrotic Syndrome (Syndrome, Nephrotic) 12/2019
1	Bullous Pemphigoid (Pemphigoid) 08/2019
1	Erythema Multiforme 02/2019
1	Melanosis (Freckles) 10/2018
1	Ulcerative Colitis 01/2018
1	Pancreatitis 01/2018
1	Crohn Disease (Crohn's Disease) 01/2018
1	Thyroiditis 01/2018
1	Colitis 01/2017
1	Autoimmune Diseases (Autoimmune Disease) 01/2017
1	Hidradenitis Suppurativa 04/2016
1	Blister (Bulla) 01/2006
1	Acute Generalized Exanthematous Pustulosis 01/2006
1	Herpes Zoster 09/2004
1	Dermatitis 09/2004

Drug/Important Bio-Agent (IBA)

20	Immune Checkpoint InhibitorsIBA 10/2023 - 01/2017
9	NivolumabIBA 11/2022 - 01/2016
9	IpilimumabIBA 11/2022 - 01/2017
7	pembrolizumabIBA 01/2022 - 01/2016
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 02/2019
3	Proteins (Proteins, Gene)FDA Link 11/2022 - 01/2019
3	AntibodiesIBA 11/2022 - 01/2016
2	Biomarkers (Surrogate Marker)IBA 05/2024 - 08/2020
2	Leucine (L-Leucine)FDA Link 12/2022 - 11/2022
2	Dihydrotachysterol (AT 10)IBA 11/2022 - 01/2020
2	avelumabIBA 11/2022 - 07/2021
2	VemurafenibIBA 01/2021 - 04/2016
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 08/2020 - 05/2019
2	Programmed Cell Death 1 ReceptorIBA 01/2020 - 01/2017
2	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 09/2004
2	HhAntag691IBA 01/2019 - 01/2017
1	Melphalan (Alkeran)FDA LinkGeneric 05/2024
1	Peptide Hydrolases (Proteases)FDA Link 05/2024
1	SteroidsIBA 03/2024
1	Infliximab (Remicade)FDA Link 03/2024
1	Immunosuppressive Agents (Immunosuppressants)IBA 03/2024
1	dabrafenibIBA 09/2022
1	trametinibIBA 09/2022
1	AntigensIBA 05/2022
1	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2021
1	Dipyrone (Metamizole)IBA 01/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2021
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2021
1	cobimetinibIBA 01/2021
1	dimemorfan (AT 17)IBA 01/2021
1	Mitogen-Activated Protein KinasesIBA 05/2019
1	Phosphotransferases (Kinase)IBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	tyrosine receptor (receptor, tyrosine)IBA 01/2019
1	NucleotidesIBA 01/2019
1	Diltiazem (Cardizem)FDA LinkGeneric 01/2006

Therapy/Procedure

20	Therapeutics 05/2024 - 10/2013
8	Immunotherapy 12/2022 - 01/2018
4	Lymph Node Excision (Lymph Node Dissection) 01/2022 - 01/2017
2	Drug Tapering 09/2022 - 01/2021
2	Drug Therapy (Chemotherapy) 01/2022 - 10/2013
2	Aftercare (After-Treatment) 06/2021 - 01/2021
1	Combined Modality Therapy 09/2023
1	Radiotherapy 01/2020